AsthmaNet: UW-Madison Clinical and Translational Research Center

AsthmaNet：威斯康星大学麦迪逊分校临床和转化研究中心

• 批准号: 8099480
• 负责人: Robert F Lemanske
• 金额: $ 83.3万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-30 至 2016-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8099480
• 关键词: Address; Adult; Adult asthma; Affect; Age; Area; Asthma; Center for Translational Science Activities; Childhood; Childhood Asthma; Clinical Research; Clinical Trials; Collaborations; Development; Doctor of Pharmacy; Education; Environment; Fostering; Human Resources; Impairment; Inflammation; Inflammatory; Institutes; Leadership; Participant; Physiological; Policies; Population; Preschool Child; Principal Investigator; Procedures; Process; Protocols documentation; Recording of previous events; Recurrence; Regimen; Relative (related person); Research; Research Infrastructure; Risk; Role; Severities; Site; Sputum; Supplementation; Symptoms; Therapy Clinical Trials; Toddler; Translational Research; Viral Respiratory Tract Infection; Vitamin D; Wheezing; Wisconsin; asthma inhaler; atopy; experience; granulocyte; high risk; improved; member; multidisciplinary; novel; response

DESCRIPTION (provided by applicant): Asthma research addressing the mechanisms of severity of symptoms, asthma control, exacerbations, and response to therapy can be optimized with a multidisciplinary network. The Madison center has been a part of the Asthma Clinical Research Network (ACRN) and the Childhood Asthma Research and Education (CARE) Network since their inceptions in 1993 and 1999, respectively. Our center has extensive experience in clinical trials, skilled study personnel, and an integrated infrastructure that will allow us to conduct asthma protocols in both adult and pediatric participants.. In addition, the Madison center is experienced in performing several physiologic studies. The Madison center has an excellent history of subject recruitment and retention and has considerable experience in creating, and fostering a spirit of collaboration. We have access to adequate recruitment populations for pediatric, adult, and severe adult asthma subjects. UW received one of the CTSAs, permitting the establishment of the UW Institute for Clinical and Translational Research (ICTR), which collaborates with numerous member sites across Wisconsin. The application describes four novel protocols that address all of the clinical research areas deemed essential in the RFA. The first main trial, termed PITSA, is a therapeutic trial in adults with severe asthma to determine if asthma control can be improved using a combination regimen directed at reducing both eosinophilic and neutrophilic inflammation and will determine if the phenotypic profile of sputum inflammatory granulocytes predicts response to the treatment. The second main trial, termed LISA, answers an important question in preschool children by comparing the relative superiority of two asthma controllers on multiple risk and impairment domains of asthma control to address an important need in high-risk toddlers with recurrent wheezing and how atopy affects response to therapy. VIVA is a proof of concept and will evaluate the contribution of vitamin D levels to asthma control and the ability to modulate control through vitamin D supplementation. VISA is an overarching (age, severity, and environment) protocol that will prospectively evaluate an important determinant of asthma control and exacerbations: viral respiratory tract infections.

描述（由申请人提供）：通过多学科网络可以优化哮喘研究，以解决症状严重程度、哮喘控制、急性发作和治疗反应的机制。自1993年和1999年成立以来，麦迪逊中心一直是哮喘临床研究网络（ACRN）和儿童哮喘研究和教育网络（CARE）的一部分。我们的中心在临床试验方面拥有丰富的经验，熟练的研究人员和综合的基础设施，使我们能够在成人和儿童参与者中进行哮喘方案。此外，麦迪逊中心在进行几项生理学研究方面经验丰富。麦迪逊中心在受试者招募和保留方面有着出色的历史，在创造和培养合作精神方面有着丰富的经验。我们有足够的儿童、成人和重度成人哮喘受试者招募人群。威斯康星大学收到了CTSA之一，允许建立临床和转化研究（ICTR），它与威斯康星州的许多成员网站合作。该申请描述了四种新型协议，这些协议涉及RFA中被认为必不可少的所有临床研究领域。第一项主要试验，称为PITSA，是一项在成人重度哮喘患者中进行的治疗性试验，旨在确定使用旨在减少嗜酸性粒细胞和嗜酸性粒细胞炎症的联合方案是否可以改善哮喘控制，并将确定痰炎性粒细胞的表型特征是否预测对治疗的反应。第二项主要试验，称为丽莎，通过比较两种哮喘控制者在哮喘控制的多个风险和损害领域的相对优势，回答了学龄前儿童的一个重要问题，以解决反复喘息的高危幼儿的重要需求，以及特应性如何影响对治疗的反应。VIVA是一个概念验证，将评估维生素D水平对哮喘控制的贡献以及通过补充维生素D调节控制的能力。VISA是一项总体（年龄、严重程度和环境）方案，将前瞻性评估哮喘控制和加重的重要决定因素：病毒性呼吸道感染。